SEC Form 4 · accession 0001213900-26-078891

InMed Pharmaceuticals Inc. · INM

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

10% Owner

10% Owner

10% Owner

10% Owner

Period of report

Jul 14, 2026

Accepted (ET)

Jul 16, 2026 · 9:58 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001728328

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Shares^F1	Jul 14, 2026	P	4,882	$1.55	A	729,277	I	By Vivo Opportunity Fund Holdings, L.P.
Common Shares^F2	Jul 14, 2026	P	493	$1.55	A	73,628	I	By Vivo Opportunity Cayman Fund, L.P.
Common Shares^F1	Jul 15, 2026	P	13,761	$1.55	A	743,038	I	By Vivo Opportunity Fund Holdings, L.P.
Common Shares^F2	Jul 15, 2026	P	1,389	$1.55	A	75,017	I	By Vivo Opportunity Cayman Fund, L.P.
Common Shares^F1	Jul 16, 2026	P	19	$1.55	A	743,057	I	By Vivo Opportunity Fund Holdings, L.P.
Common Shares^F2	Jul 16, 2026	P	2	$1.55	A	75,019	I	By Vivo Opportunity Cayman Fund, L.P.

No Table II lines on this filing.

F1Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F2Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.